Neue Daten und Perspektiven in der hormonellen Behandlung postmenopausaler Patientinnen mit Tibolon

Abstract

GebFra, Artikel GEB880, Roßberg [282], Ausdruck vom 21.3.2001 Abb. 1 Kumulative Anzahl der Frauen, die die Studie [29] wegen unakzeptabler Blutungen oder Schmierblutungen beendeten (& Tibolon Liviella ® , s E 2 /NETA Kliogest ® ; mit Genehmigung des Autors).

Hormone replacement therapy with tibolone: effects on sexual functioning in postmenopausal women

“…Therefore, the purpose of this study was to compare, in a large population of postmenopausal women requiring HRT for climacteric symptoms, the baseline degree of sexual dysfunction with the same subjective reports evaluated after 4 months of tibolone using a questionnaire already successfully evaluated in other fields of medicine (9, 10). The reason we opted for tibolone (Liviel ® , 1 × 2.5 mg/day; Organon GesmbH, Vienna, Austria) as HRT is that this synthetic steroid hormone, which has been used in the treatment of postmenopausal complaints (11), has a unique pharmacological profile combining not only estrogenic and progestogenic but also weak androgenic properties (12). Because HRT is widely accepted in women suffering from climacteric complaints, a double‐blind, placebo‐controlled trial was not considered feasible.…”